Nivolumab (Opdivo) Concentrate for Infusion from Japan
Nivolumab is a human monoclonal antibody PD-1 inhibitor for melanoma and lung cancer immunotherapy. Classified in HTS 3002.15.00.11 as it directly regulates immunological processes via checkpoint inhibition, in measured retail vials.
Duty Rate — Japan → United States
15%
Rate breakdown
9903.04.6215%Patented pharmaceutical articles that are the product of Japan, of a European Union member country, of South Korea, of Switzerland, or of Liechtenstein as provided for in subdivisions (c) and (f) of U.S. note 40 to this subchapter
9903.05.860%Articles provided for in subdivision (b) of U.S. note 52 to this subchapter
9903.05.900%Articles of aluminum, of steel or of copper or derivative aluminum or steel articles; passenger vehicles (sedans, sport utility vehicles, crossover utility vehicles, minivans and cargo vans) and light trucks; parts of passenger vehicles (sedans, sport utility vehicles, crossover utility vehicles, minivans and cargo vans) and light trucks; medium- and heavy-duty vehicles; parts of medium- and heavy-duty vehicles; wood products; patented pharmaceutical articles; and semiconductor articles, as provided in subdivision (f) of U.S. note 52 to this subchapter
Import Tips
• Provide PD-1 binding assay data; ensure oncology-specific FDA pathways
• Use validated cold chain with data loggers for immunotherapy stability